Javier Martinez-Useros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1920208/publications.pdf

Version: 2024-02-01

22 papers 798 citations

16 h-index 677142 22 g-index

22 all docs 22 docs citations

times ranked

22

1663 citing authors

#	Article	IF	CITATIONS
1	Obesity and colorectal cancer: molecular features of adipose tissue. Journal of Translational Medicine, 2016, 14, 21.	4.4	133
2	UNR/CSDE1 Drives a Post-transcriptional Program to Promote Melanoma Invasion and Metastasis. Cancer Cell, 2016, 30, 694-707.	16.8	131
3	Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. Journal of Clinical Medicine, 2017, 6, 29.	2.4	88
4	Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. Oncotarget, 2016, 7, 47954-47965.	1.8	66
5	KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells, 2020, 9, 219.	4.1	46
6	The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Oral Oncology, 2015, 51, 423-430.	1.5	39
7	New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. International Journal of Molecular Sciences, 2018, 19, 2468.	4.1	27
8	Identification of prefrontal cortex protein alterations in Alzheimer's disease. Oncotarget, 2018, 9, 10847-10867.	1.8	27
9	Identification of tumor-associated antigens with diagnostic ability of colorectal cancer by in-depth immunomic and seroproteomic analysis. Journal of Proteomics, 2020, 214, 103635.	2.4	26
10	Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?. BioMed Research International, 2016, 2016, 1-13.	1.9	25
11	UNR/CSDE1 Expression Is Critical to Maintain Invasive Phenotype of Colorectal Cancer through Regulation of c-MYC and Epithelial-to-Mesenchymal Transition. Journal of Clinical Medicine, 2019, 8, 560.	2.4	25
12	DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. BMC Cancer, 2014, 14, 965.	2.6	24
13	Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments. Cancers, 2021, 13, 3209.	3.7	24
14	Multiplexed Biosensing Diagnostic Platforms Detecting Autoantibodies to Tumor-Associated Antigens from Exosomes Released by CRC Cells and Tissue Samples Showed High Diagnostic Ability for Colorectal Cancer. Engineering, 2021, 7, 1393-1412.	6.7	20
15	The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance. Cancers, 2021, 13, 322.	3.7	19
16	The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. BioMed Research International, 2016, 2016, 1-8.	1.9	18
17	UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. PLoS ONE, 2017, 12, e0182044.	2.5	16
18	The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1275.	2.4	15

#	Article	IF	CITATIONS
19	Spatial Proteomic Analysis of Isogenic Metastatic Colorectal Cancer Cells Reveals Key Dysregulated Proteins Associated with Lymph Node, Liver, and Lung Metastasis. Cells, 2022, 11, 447.	4.1	13
20	The Clinical Significance of PIWIL3 and PIWIL4 Expression in Pancreatic Cancer. Journal of Clinical Medicine, 2020, 9, 1252.	2.4	10
21	Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Pathology and Oncology Research, 2019, 25, 269-278.	1.9	3
22	The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models. Cancers, 2021, 13, 2778.	3.7	3